|drug1726||High Oxalate Diet Wiki||1.00|
|drug2186||Low Oxalate Diet Wiki||1.00|
There is one clinical trial.
This study consists of having subjects, those with calcium oxalate kidney stones as well as healthy controls, consume low and oxalate enriched diets to investigate the role of oxalate on crystalluria (the presence of crystals in urine), immunity and infection.
Description: Twenty-four hour urinary oxalate will be reported as mg/dayMeasure: Urinary Oxalate Time: Change between Baseline and Diets at 4 days
Description: Twenty-four hour crystalluria will be reported as particles/mlMeasure: Crystalluria Time: Change between Baseline and Diets at 4 days
Description: Cellular bioenergetics will be reported as oxygen consumption rateMeasure: Monocyte Cellular Bioenergetics Time: Change between Baseline and Diets at 4 days
Description: Monocyte mitochondrial complex activity will be reported as oxygen consumption rateMeasure: Monocyte Mitochondrial Complex Activity Time: Change between Baseline and Diets at 4 days
Description: Monocyte transcriptomics will be reported as gene expression (mRNA levels)Measure: Monocyte Transcriptomics Time: Change between Baseline and Diets at 4 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports